-$0.21 EPS Expected for Correvio Pharma Corp (NASDAQ:CORV) This Quarter

Analysts forecast that Correvio Pharma Corp (NASDAQ:CORV) will post earnings per share of ($0.21) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Correvio Pharma’s earnings, with estimates ranging from ($0.22) to ($0.20). Correvio Pharma reported earnings of ($0.37) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 43.2%. The firm is expected to report its next earnings report on Tuesday, August 13th.

According to Zacks, analysts expect that Correvio Pharma will report full year earnings of ($0.76) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.65). For the next financial year, analysts forecast that the business will post earnings of ($0.43) per share, with EPS estimates ranging from ($0.59) to ($0.23). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Correvio Pharma.

Correvio Pharma (NASDAQ:CORV) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.04). Correvio Pharma had a negative return on equity of 375.42% and a negative net margin of 58.25%. The business had revenue of $7.25 million for the quarter, compared to analyst estimates of $7.91 million.

CORV has been the subject of a number of recent research reports. Canaccord Genuity set a $22.00 price objective on shares of Hibbett Sports and gave the stock a “hold” rating in a research note on Monday, March 25th. HC Wainwright restated a “neutral” rating on shares of Rewalk Robotics in a research note on Friday, March 15th. Finally, ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Correvio Pharma currently has a consensus rating of “Buy” and a consensus price target of $8.17.

Several institutional investors have recently bought and sold shares of the company. ARS Investment Partners LLC boosted its stake in shares of Correvio Pharma by 1.2% during the 1st quarter. ARS Investment Partners LLC now owns 337,868 shares of the company’s stock worth $1,068,000 after buying an additional 4,013 shares during the last quarter. BlackRock Inc. acquired a new stake in Correvio Pharma in the 4th quarter valued at about $39,000. Columbia Pacific Advisors LLC lifted its stake in Correvio Pharma by 29.8% in the 1st quarter. Columbia Pacific Advisors LLC now owns 130,709 shares of the company’s stock valued at $413,000 after purchasing an additional 30,000 shares during the last quarter. Financial Counselors Inc. acquired a new stake in Correvio Pharma in the 1st quarter valued at about $116,000. Finally, Westfield Capital Management Co. LP lifted its stake in Correvio Pharma by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,788,032 shares of the company’s stock valued at $15,130,000 after purchasing an additional 50,228 shares during the last quarter. Institutional investors own 46.15% of the company’s stock.

Shares of Correvio Pharma stock traded down $0.03 during trading hours on Friday, reaching $2.00. 38,992 shares of the company’s stock were exchanged, compared to its average volume of 109,221. The business’s 50 day moving average is $2.23. Correvio Pharma has a fifty-two week low of $1.92 and a fifty-two week high of $5.24. The company has a current ratio of 2.80, a quick ratio of 2.42 and a debt-to-equity ratio of 7.21. The firm has a market cap of $83.27 million, a PE ratio of -2.25 and a beta of 0.49.

About Correvio Pharma

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Read More: Trading on Margin

Get a free copy of the Zacks research report on Correvio Pharma (CORV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.